User:Mr. Ibrahem/Binimetinib

Binimetinib, sold under the brand name Mektovi, is as medication used to treat melanoma. Specifically it is used with encorafenib for cases that are BRAF V600 positive and cannot be removed by surgery. It is taken by mouth.

Common side effects include tiredness, nausea, diarrhea, and abdominal pain. Other side effects may include heart damage, blood clots, eye problems, interstitial lung disease, liver problems, muscle breakdown, and bleeding. Use in pregnancy may harm the baby. It works by blocking MEK, preventing its activation by BRAF, thereby slowing cancer growth.

Binimetinib was approved for medication use in the United States and Europe in 2018. In the United Kingdom 4 weeks of treatment costs the NHS about £4,500 as of 2021. This amount in the United States costs about 12,800 USD.